Early access
Sign in
Taking peoplePhase 3

Blood thinners or antiplatelet drugs for vein clots in antiplatelet users

Compares blood thinners and antiplatelet drugs for new vein clots.

Key facts

Who runs it
Centre Hospitalier Universitaire de Saint Etienne
Where
France33 sites in 1 countryChoose a country to see its sites
Registry title
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
Status
Recruiting
Phase
Phase 3
People taking part
1,400 people, planned
Started
16 Aug 2023
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Full-dose anticoagulant therapy (AC)
  • Antiplatelet therapy (AP)
Record updated
8 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a new blood clot in a deep leg vein or in the lungs. They must already take antiplatelet medicine for heart or blood vessel disease caused by narrowed arteries.

Age
18 Years and older
Sex
All sexes can join.
Disease stage
A sudden, confirmed blood clot with symptoms: in a deep vein at or above the knee (popliteal vein or higher), or in the lungs (pulmonary embolism). Full-dose blood thinner treatment is planned for at least 3 months. Life expectancy is more than 3 months.
Earlier treatment
People must be taking antiplatelet medicine to prevent new problems from known artery disease when the clot is found. People cannot join if they have had blood thinners for more than 5 days before being assigned to a group.

Main reasons for not taking part

  • Active bleeding, a high bleeding risk that rules out blood thinners, or blood pressure above 180 mm Hg systolic or 110 mm Hg diastolic.
  • Pregnancy, planned pregnancy, or no effective birth control.
  • A clot only in the lower leg veins below the knee.
  • Antiplatelet medicine taken only to prevent a first heart problem, or a need to stay on two antiplatelet medicines.
  • Triple positive antiphospholipid syndrome with artery clots, or a recent major heart or brain event (12 months for acute coronary syndrome, 6 months for stroke-type or leg artery disease).

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Signed informed consent
  • Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb
  • Indication of full-dose anticoagulant therapy for at least 3 months
  • Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis
  • Life expectancy more than 3 months
  • Social security affiliation

Who cannot take part

  • Anticoagulation for more than 5 days prior to randomization
  • Indication to maintain a dual-antiplatelet therapy
  • Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg
  • Isolated distal deep vein thrombosis
  • Antiplatelet therapy prescribed for primary prevention of cardiovascular disease
  • Triple positive antiphospholipid syndrome, with arterial thrombosis
  • Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrome, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases
  • Unable to give informed consent
  • Active pregnancy or expected pregnancy or no effective contraception

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients.

Read full original descriptionShow less

Their management requires use of antithrombotic agents: anticoagulant therapy (AC) for secondary prevention of VTE recurrence, antiplatelet (AP) for secondary prevention of major adverse ischemic cardiovascular and cerebrovascular event (MACCE) in patients with atherosclerotic cardiovascular disease (coronary artery disease, atherosclerotic cerebrovascular disease, lower extremity peripheral arterial disease).

Side effects of antithrombotic drugs are the 1st cause of emergency admission and hospitalization for an adverse drug reaction (mainly bleeding), and the combination of AC with AP strongly increases this risk.

The 2 groups in the trial

  • strategy of full-dose anticoagulant therapy alone (AC)Treatment being tested

    The experimental group receiving full-dose anticoagulant therapy alone (AC). Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE Antiplatelet therapy will be stopped.

    Treatment: Full-dose anticoagulant therapy (AC)

  • strategy of combined full-dose anticoagulant and antiplatelet therapies (AC+AP)Existing treatment, for comparison

    The control group receiving the standard of care: Antiplatelet therapy will be combined to full-dose anticoagulant therapy. Anticoagulant (AC) therapy :at the investigator's discretion in accordance with international recommendations for the management of DVT/PE Antiplatelet (AP) therapy : Aspirin or Clopidogrel

    Treatment: Full-dose anticoagulant therapy (AC) and Antiplatelet therapy (AP)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
Plain-language title
Blood thinners or antiplatelet drugs for vein clots in antiplatelet usersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
8 May 2026